Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses. Read more
Dr. Benjamin Besse recently discussed detailed findings from the now discontinued CARMEN-LC03 trial. Read more
Dr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression. Read more
Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort. Read more
The session will also include late-breaking data from HARMONi-2, NeoCOAST-2, and TROPION-Lung01 as well as an address from IASLC President Dr. Paul Van Schil. Read more
Drs. Jyoti Patel and Khyati Somayaji Dasika say the increased burden of lung cancer on women underscores the necessity for gender-sensitive approaches in healthcare policy, research, and clinical practice. Read more
While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population. Read more
In an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative. Read more
Dr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA. Read more